Shots:
Pfizer has discontinued the development of danuglipron (PF-06882961) as a potential therapy for chronic weight management
Danuglipron was evaluated in 2 P-I trials (NCT06567327 & NCT06568731), meeting key PK objectives & confirming formulation & dose with potential for strong efficacy & tolerability in P-III. However, a case of drug-induced liver injury & recent regulatory input led…
